Resources

Resources designed for you in your practice

OPTIMUM Phase III Study Profile

The efficacy and safety results from the OPTIMUM study, a Phase III superiority study of PONVORY^® vs teriflunomide in patients with RMS

PONVORY^® Information Booklet

An overview of PONVORY^® that can aid in your treatment decisions for patients with RMS

We would be happy to assist you.

DISCOVER the convenience and flexibility of PONVORY^®

SEE overall rates of treatment emergent adverse events vs teriflunomide from OPTIMUM

FIND OUT more about how PONVORY^® works

RMS=relapsing multiple sclerosis

Contact your local Janssen Account Manager

Request Medical Information

Stay in Touch with Janssen